5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

The same started a few weeks ago, and that’s a list of potential catalyst penny stocks. One of the interesting things about specific industries like biotechnology is that companies tend to announce a date in advance when news will be out in the future. Whether it’s something like the Prescription Drug Use Charges Act (PDUFA) date with the FDA or the new data readings, there’s a lot to keep an eye on. In most cases, biotech companies will let the public know the timing of things like this.

The important part is deciding whether upcoming events are potential bullish or bearish catalysts. As I’m sure many of you know, biotechnology is a fickle area of ​​the market. Companies can put out positive data, but if one thing is missed or falls short of expectations, an upbeat report could become the reason for a sell-off in penny stocks. Last week, we discussed the top 10 Penny stocks to watch for potential biotech catalysts. Of the stocks discussed, some climbed to new September highs while others fell. But the more you know, the better prepared you will be for what might be in store.

Read more: Top Penny Stocks To Watch Under $1 In October 2021

In this article, we’ll take a look at 5 penny stocks to watch this week with potential catalysts. Some have given specific dates, while others have given time frames. After you get your hands on the ground, you can decide for yourself if they are the best penny stocks to buy this week or you should avoid them altogether.

Penny stocks to watch this week

Company	Day
first. Arbutus Biopharma (NASDAQ: ABUS)	October 5, 2021 & October 7, 2021
2. Kaleido Biosciences Inc. (NASDAQ: KLDO)	October 5, 2021
3. MannKind Corporation (NASDAQ: MNKD)	October 5, 2021
4. Adverum Biotechnologies Inc. (NASDAQ: ADVM)	October 9, 2021
5. Trevena Inc. (NASDAQ: TRVN)	October 9, 2021

Penny stocks to watch on October 5:

Arbutus Biopharma

The first name on this week’s list of penny stocks to watch is Arbutus. We discussed the company many times. However, if you’re new to it, let’s get you up to speed. Arbutus focuses on treatments for chronic infections, including hepatitis B, and new therapies to treat coronaviruses. A greater amount of attention has been focused on Arbut than on Moderna, believe it or not. Two conflicting lipid formulations of Arbutus for the delivery of nucleic acids.

Last month, the European Patent Office said its patent 069 relating to lipid formulations was “Patent” (valid). This is consistent with the response of the US Patent and Trademark Office after the agency issued its permission notice in September. Moderna is continuing with an appeal set for a hearing in this month. However, if Arbutus is right, it could open the door to eligibility for royalties from Moderna’s COVID-19 vaccine sales.

What to Watch with ABUS Stock This Week

This week there are some things to follow with Arbutus. The first came on October 5. The company presented at the first 2 conferences planned. Arbutus will participate in a fireside chat at the Chardan Genetic Drugs Conference starting at 4:30 p.m. ET.

Read more: Best Penny Stocks to Watch in the First Week of October

This weekend, things could also put ABUS stock in the spotlight. On October 7, the United States Court of Appeals will hear Arbutus and Moderna’s arguments. So if ABUS or mRNA stocks, for that matter, are on your list this week, keep this date in mind.

Kaleido Biosciences Inc.

One of the notable penny stocks in this week’s events is Kaleido Biosciences. The company is not too active in the stock market. However, around specific events, KLDO stock has had some fluctuations. Looking back this summer, you’ll see a spike in June. This comes just days after Kaleido’s presentation at the JMP Securities Life Science Conference. As to whether the Conference is an official catalyst or not. The latter, and you’ll also see a spike as the company presents at other conferences this year, including most recently in September at the Morgan Stanely Global Healthcare Conference.

Kaleido’s core focus is on the Microbiome Metabolic Therapy (MMT) platform. Its handling of KB295 is also something that traders have followed. It is being studied in patients with mild to moderate ulcerative colitis. Meanwhile, the other side of Kaleido focuses on the Long-Hauler COVID patient. The company’s KB109 is being evaluated for COVID-19.

What to watch with KLDO stock this week

This week, the market may be a little clearer on where all of Kaleido’s treatments are. On October 5, the company hosted an R&D presentation to discuss clinical data and progress of the pipeline. This program includes corporate strategy, data from the non-IND study evaluating KB295, and preclinical data supporting the advancement of KB109 in patients with COPD.

MannKind Corporation

There are other companies like MannKind, which have previously announced pending updates. However, the company did not give a specific date, but only said that October will be a month to note.

MannKind specializes in inhaled therapeutic products. Indications include endocrinology and orphan lung disease. Afrezza® Inhalation Powder is the company’s first FDA-approved product and the only ultra-fast-acting mealtime inhaled insulin in the United States. MannKind is also preparing to produce Tyvaso DPI™ in partnership with United Therapeutics. Tyvaso DPI is under FDA review for the treatment of pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD).

What to watch with MNKD stock This week

This week and this month can be very important for MannKind. First, on October 5, the company participated in the Lytham Partners Fall Investor Conference. CEO Michael Castagna, PharmD, will discuss various aspects of the company.

Additionally, although a specific date has not been given, the September update discussed that FDA action on a New Drug Application (NDA) for Tyvaso DPI is expected this month. This comes after United Therapeutics submitted an NDA to the FDA seeking approval from Tyvaso DPI to treat adult patients with PAH and PAH. PH-ILD.

Penny stocks to watch on October 9:

Adverum Biotechnologies Inc.

Last week Adverum kicked off the month of industry presentations at the Retina Society’s Scientific Meeting on October 1. Considering that the presentation doesn’t start below 4 p.m. ET, there could be more details to come. Getting ready to start a new week. Furthermore, Adverum will present at two more conferences this month, the second taking place this week. The company provides data from the Phase 2 INFINITY Trial using ADVM-022 in diabetic macular edema.

Read more: 5 Short-Term Penny Stocks To Buy For Under $5 Right Now

The company has been in the spotlight over the past few months as it refines its gene therapy candidate. There are also plans to complete data analysis by year-end to develop a protocol and to seek investigator and regulatory feedback on the Phase 2 clinical trial in wet AMD.

What to Watch with ADVM Stock This Week

This week, October 9, will be the day to focus on. This is where the company offers Phase 2 Data on ADVM-022. Following this presentation, Adverum will also present results from the Phase 1 OPTIC Trial in ADVM-022-treated neovascular AMD. These won’t come early next week at the ASRS Science Meeting (we’ll update next week).

Trevena Inc.

Trevena is one of the other penny stocks in the spotlight thanks to COVID-19. Last week, the company announced the results of a proof-of-concept study TRV027 on patients with the virus. Insights suggest a 92% probability of TRV027 having a potentially beneficial effect on the primary endpoint of D-dimer levels. This is a biomarker associated with critical illness and mortality. The company also reported that treated patients had an average hospital stay 12 days lower than placebo.

In addition to TRV027, Trevena develops treatments for central nervous system disorders. This includes an approved product in the United States, OLINVYK® (oliceridine) injection. This is indicated in adults for the management of acute pain severe enough to require intravenous opioid analgesics and for whom alternative treatments are not appropriate.

What to watch with TRVN stock this week

This week, Trevena’s OLINVYK® will be a focal point. Earlier in the year, two abstracts were accepted at ANESTHESIOLOGY® 2021. Both abstracts highlighted safety data from the OLINVYK (oliceridine) injection program. The meeting is sponsored by the American Association of Anesthesiologists and will be shown on October 9.

Penny stocks to watch this week

There’s a lot to see this week. Biotech penny stocks are part of that, and it is essential to understand that companies with upcoming events are not “sures” to see a move (up or down). . At the very least, though, there might be some new information to consider if any of this is on your list of penny stocks. Will that be the case this week?